Full Year Results 

Indivior increases legal provisions

Indivior increases legal provisions

Indivior's shareholders (INDV) were spooked by news the drug manufacturer was forced to increase its provisions for a plethora of investigative and antitrust litigation matters in 2017, to $438m (£312m), from the $217m carried during its third-quarter. That included its ongoing dispute with Dr Reddy's, after a US court ruled an unbranded version of its opioid addiction treatment Suboxone did not breach Indivior's patent. 

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now